2023

Immunotherapy and Targeted Therapy Increase Melanoma Survival and Health Care Burden

Among patients with invasive melanoma, improvements in overall survival (OS) rates due to the adoption of immunotherapy and targeted systemic therapies are further associated with greater economic and time burdens on the health care system, according to study results published in the Journal of the American Medical Association Dermatology.

Read More
MRV News
Melanoma News
Archive
Menu